DADE BEHRING INC
10-Q, EX-27, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: DADE BEHRING INC, 10-Q, EX-10.10, 2000-11-14
Next: THCG INC, 10-K/A, 2000-11-14



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>                       <C>
<PERIOD-TYPE>                   3-MOS                     9-MOS
<FISCAL-YEAR-END>                         DEC-31-2000                DEC-31-2000
<PERIOD-START>                            JUL-01-2000                JAN-01-2000
<PERIOD-END>                              SEP-30-2000                SEP-30-2000
<CASH>                                         24,300                     24,300
<SECURITIES>                                        0                          0
<RECEIVABLES>                                 291,800                    291,800
<ALLOWANCES>                                        0                          0
<INVENTORY>                                   251,900                    251,900
<CURRENT-ASSETS>                              662,800                    662,800
<PP&E>                                        347,000                    347,000
<DEPRECIATION>                                      0                          0
<TOTAL-ASSETS>                              1,609,700                  1,609,700
<CURRENT-LIABILITIES>                         339,900                    339,900
<BONDS>                                             0                          0
                               0                          0
                                         0                          0
<COMMON>                                            0                          0
<OTHER-SE>                                  (218,200)                  (218,200)
<TOTAL-LIABILITY-AND-EQUITY>                1,609,700                  1,609,700
<SALES>                                       292,300                    896,800
<TOTAL-REVENUES>                              292,300                    896,800
<CGS>                                         148,200                    422,100
<TOTAL-COSTS>                                 152,400                    455,200
<OTHER-EXPENSES>                              (6,900)                    (8,700)
<LOSS-PROVISION>                                    0                          0
<INTEREST-EXPENSE>                             39,400                    109,200
<INCOME-PRETAX>                              (40,800)                   (81,000)
<INCOME-TAX>                                 (10,400)                   (22,600)
<INCOME-CONTINUING>                          (30,400)                   (58,400)
<DISCONTINUED>                                      0                          0
<EXTRAORDINARY>                                     0                          0
<CHANGES>                                           0                          0
<NET-INCOME>                                 (30,400)                   (58,400)
<EPS-BASIC>                                         0                          0
<EPS-DILUTED>                                       0                          0



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission